O. Hamid

发表

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

R. Bouabdallah, M. Dyer, R. Kurzrock, 2020, Clinical lymphoma, myeloma & leukemia.

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

J. Hecht, P. LoRusso, J. Hecht, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.

T. Gauler, A. Dietz, O. Hamid, 2013, European journal of cancer.

A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas.

O. Hamid, D. Gómez-Almaguer, Neil V. Smith, 2013, Clinical lymphoma, myeloma & leukemia.

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

J. Reeves, J. Hainsworth, O. Hamid, 2016, Targeted Oncology.

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

A. Jimeno, J. Welsh, J. Grilley-Olson, 2020, Journal for ImmunoTherapy of Cancer.

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

A. Oza, H. Hirte, E. Kaldjian, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.

R. Salgia, D. Spigel, O. Hamid, 2017, Lung cancer.

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

A. Verma, G. Martinelli, R. Walgren, 2018, Leukemia research.

Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

J. Reeves, J. Hainsworth, O. Hamid, 2015 .

Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.

M. Kohli, D. Petrylak, R. Walgren, 2015 .

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

J. Hecht, A. Benson, A. Shields, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.

O. Hamid, 2004, Journal of the American Pharmacists Association : JAPhA.

Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3.

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

J. Hainsworth, L. Fayad, O. Hamid, 2016, Leukemia & lymphoma.

Phase I I T rial o f I ntravenous C I-1042 i n P atients W ith Metastatic C olorectal C ancer

A. Shields, E. Galanis, J. Hecht, 2003 .

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Y. Bang, Yoon-Koo Kang, J. Tie, 2017, Targeted Oncology.

Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)

J. Blando, J. Mazières, Y. Zheng, 2022, Cancer Research.

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma

T. Kuzel, P. Porcu, C. Querfeld, 2011, Leukemia & lymphoma.

Open‐label, single‐arm, phase II study of enzastaurin in patients with follicular lymphoma

Tuan S. Nguyen, I. Flinn, R. Hermann, 2014, British journal of haematology.

Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

C. Sternberg, C. Szczylik, B. Escudier, 2012, American journal of clinical oncology.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

T. Powles, H. Nishiyama, H. Harputluoglu, 2019, The Lancet. Oncology.

LBA4_PRRANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

T. Powles, H. Nishiyama, C. Sternberg, 2017 .

929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study

J. Blando, O. Hamid, P. Forde, 2022, Annals of Oncology.

730MO First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies

J. Janik, A. Balmanoukian, O. Hamid, 2022, Annals of Oncology.

Phase II Tria l o f Intravenous CI-1042 in Pat ients With Metastat ic Colorecta l Cancer

A. Benson, A. Shields, E. Galanis, 2003 .

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

I. Lowy, O. Hamid, V. Janković, 2022, Annals of Oncology.

Abstract CT058: Phase I study of LY2874455, a fibroblast growth factor (FGF) receptor inhibitor, in patients with advanced cancer

Y. Bang, Yoon-Koo Kang, J. Tie, 2016 .

Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.

J. Hainsworth, O. Hamid, L. Fayad, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1472PPHASE II STUDY OF CARBOPLATIN/ETOPOSIDE PLUS LY2510924, A CXCR4 PEPTIDE ANTAGONIST, VERSUS CARBOPLATIN/ETOPOSIDE IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC).

R. Salgia, D. Spigel, O. Hamid, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).

R. Salgia, D. Spigel, O. Hamid, 2015 .